BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 3909337)

  • 1. Infections due to gram-negative bacteria: an overview.
    Neu HC
    Rev Infect Dis; 1985; 7 Suppl 4():S778-82. PubMed ID: 3909337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of aztreonam in the treatment of serious infections due to multiresistant gram-negative organisms, including Pseudomonas aeruginosa.
    Scully BE; Neu HC
    Am J Med; 1985 Feb; 78(2):251-61. PubMed ID: 4038574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aztreonam therapy for serious gram-negative bacillary infections.
    Cone LA; Woodard DR
    Rev Infect Dis; 1985; 7 Suppl 4():S794-802. PubMed ID: 3909339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current state of infectious diseases--potential areas of directed therapy with aztreonam.
    Neu HC
    Am J Med; 1985 Feb; 78(2A):77-80. PubMed ID: 4038580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aztreonam in the treatment of bone and joint infections caused by gram-negative bacilli.
    Simons WJ; Lee TJ
    Rev Infect Dis; 1985; 7 Suppl 4():S783-8. PubMed ID: 2934786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aztreonam: the first monobactam.
    Neu HC
    Med Clin North Am; 1988 May; 72(3):555-66. PubMed ID: 3280906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of changing pathogens and antimicrobial susceptibility patterns in the treatment of serious infections in hospitalized patients.
    Jones RN
    Am J Med; 1996 Jun; 100(6A):3S-12S. PubMed ID: 8678095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Microbiological profiles of pathogens causing nosocomial bacteremia in 2011, 2013 and 2016].
    Wang X; Zhao C; Li H; Chen H; Jin L; Wang Z; Liao K; Zeng J; Xu X; Jin Y; Su D; Liu W; Hu Z; Cao B; Chu Y; Zhang R; Luo Y; Hu B; Wang H
    Sheng Wu Gong Cheng Xue Bao; 2018 Aug; 34(8):1205-1217. PubMed ID: 30152206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical evaluation of aztreonam therapy for serious infections due to gram-negative bacteria.
    McKellar PP
    Rev Infect Dis; 1985; 7 Suppl 4():S803-9. PubMed ID: 3909340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gram-negative bacteremia. III. Reassessment of etiology, epidemiology and ecology in 612 patients.
    Kreger BE; Craven DE; Carling PC; McCabe WR
    Am J Med; 1980 Mar; 68(3):332-43. PubMed ID: 6987870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of gram-negative infections with aztreonam.
    Simons WJ; Lee TJ
    Am J Med; 1985 Feb; 78(2A):27-30. PubMed ID: 4038577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gram-negative bacillary pneumonia in the nosocomial setting. Role of aztreonam therapy.
    Cook JL
    Am J Med; 1990 Mar; 88(3C):34S-37S; discussion 38S-42S. PubMed ID: 2316557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pneumonia caused by gram-negative bacilli: an overview.
    Levison ME; Kaye D
    Rev Infect Dis; 1985; 7 Suppl 4():S656-65. PubMed ID: 3909320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of aztreonam in lower respiratory tract infections.
    Cook JL
    Urology; 1988 Jun; 31(6 Suppl):33-6. PubMed ID: 3287748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temocillin treatment of serious infections due to gram-negative bacilli in an intensive care unit.
    Offenstadt G; Lesage D; Hericord P; Pinta P; Leaute JB; Amstutz P
    Drugs; 1985; 29 Suppl 5():213-20. PubMed ID: 3896741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Summary of worldwide clinical trials of aztreonam in patients with urinary tract infections.
    Swabb EA; Jenkins SA; Muir JG
    Rev Infect Dis; 1985; 7 Suppl 4():S772-7. PubMed ID: 3909336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aztreonam: worldwide overview of the treatment of patients with gram-negative infections.
    Henry SA; Bendush CB
    Am J Med; 1985 Feb; 78(2A):57-64. PubMed ID: 3881950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aztreonam activity, pharmacology, and clinical uses.
    Neu HC
    Am J Med; 1990 Mar; 88(3C):2S-6S; discussion 38S-42S. PubMed ID: 2180293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical experience with aztreonam.
    Stutman HR
    Pediatr Infect Dis J; 1989 Sep; 8(9 Suppl):S109-12; discussion S128-32. PubMed ID: 2682508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of aztreonam and tobramycin in the treatment of lower respiratory tract infections caused by gram-negative bacilli.
    Nolen TM; Phillips HL; Hall HJ
    Rev Infect Dis; 1985; 7 Suppl 4():S666-8. PubMed ID: 3909321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.